- Apollo Hospital, Chennai introduces the first digital PET/CT - Biograph Vision™, which brings new level of precision to PET/CT imaging
- The first of its kind digital PET/CT, verifying proton beam therapy and efficacy of treatment for various cancers at early stage
- Safeguarding patients from negative side effects, reducing ineffective therapies and saving costs made possible with early response effectively detected through Biograph Vision™
With nearly a million new cancer cases diagnosed per annum in India, staging disease more accurately and defining treatment strategies better is the need of the hour. With the introduction of Biograph Vision™ in India, addressing cancer progression with personalized medicine will help deliver the right treatment to the right patient and at the right time.
PET/CT is indispensable as a diagnostic and prognostic tool in the assessment of patient response to cancer therapy and cancer recurrence. The Biograph Vision™ from Siemens Healthineers enables a better understanding of disease progression and treatment resistance, to define treatments that can be precisely tailored for patients.
“Biograph Vision™ is designed for improved accuracy, performance, and reproducibility to deliver a whole new world of precision in PET/CT imaging. With the market’s fastest time-of-flight and highest effective sensitivity, Biograph Vision™ helps reduce scan time and injected dose, reducing patient exposure to radiation. With the introduction of Biograph Vision™ Siemens Healthineers is helping Apollo Proton Cancer Centre in Chennai to enhance the quality of patient care and expand precison medicine.” said, Mr. Vivek Kanade, Executive Director, Siemens Healthineers, India.
Dr. Prathap C Reddy, Chairman, Apollo Hospitals Group said, “Our patient centric ethos has always motivated us to invest in the best available for our patients and Apollo has been at the forefront of introducing cutting edge technologies in India and the region. Apollo Proton Cancer Centre in Chennai has ushered new hope for over 3.5 billion people, who earlier would have had to travel to the western world to access Proton Therapy, the world’s most advanced radiation therapy. Increasingly Proton Therapy is becoming the standard of care for several cancers and its unique edge of minimal side effects is transforming quality of cancer survivorship.”
Speaking about the benefits, Ms. Suneeta Reddy, Managing Director, Apollo Hospitals added, “The DNA of Apollo Hospitals is clinical excellence and achieving clinical outcomes on par with the world’s best centres. Each of our investments including the Siemens Healthineers’ Biograph Vision™ at our new Apollo Proton Cancer Centre underscores this spirit and commitment to provide an international standard of care for our patients. “
Unique advances in Biograph Vision™ offer an opportunity to manage dose reduction, reduce scan time, and more accurately detect small lesions. Finally, it leads to increased accuracy of diagnosis, improves system performance, and helps clinicians understand disease progress by improving reproducibility in quantification, benefitting patients with precision medicine. Innovation in Digital PET/CT with Ultra Dynamic Range (UDR) detector technology brings clinicians vast improvements in system sensitivity due to the improvement of Time-of-Flight technology, volumetric resolution by using small (3.2 mm x 3.2 mm) LSO crystals and qualitative accuracy.
With the market’s fastest time-of-flight at 214 ps and the highest effective sensitivity at 100 cps/kBq, Biograph Vision™ helps to reduce scan time by a factor of 3.9 to improve patient throughput as well as reduce patient radiation exposure and tracer cost.
Improved patient comfort and positioning as well as advanced applications in radiation therapy planning is enabled through the system’s 78 cm bore. Biograph Vision™ is also designed to reduce unnecessary exposure to CT radiation, provide greater patient comfort and decreased examination time, thereby sparing patients from harmful side effects.
Siemens Healthineers enables healthcare providers worldwide to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving patient experience and digitalizing healthcare. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services.
In fiscal 2018, which ended on September 30, 2018, Siemens Healthineers generated revenue of €13.4 billion and adjusted profit of €2.3 billion and has about 50,000 employees worldwide. Further information is available at www.siemens-healthineers.co.in.